PCV13 Pediatric Routine Schedule Completion and Adherence Before and During the COVID-19 Pandemic in the United States.
Adherence
COVID-19
Completion
Pediatric vaccination
Pneumococcal conjugate vaccine
Journal
Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
06
05
2022
accepted:
12
09
2022
pubmed:
12
10
2022
medline:
12
10
2022
entrez:
11
10
2022
Statut:
ppublish
Résumé
A 13-valent pneumococcal conjugate vaccine (PCV13) was licensed to protect against emerging Streptococcus pneumoniae serotypes. Healthcare services, including routine childhood immunizations, were disrupted as a result of coronavirus disease 2019 (COVID-19). This study compared PCV13 routine vaccination completion and adherence among US infants before and during the COVID-19 pandemic and the relationship between primary and booster dose completion and adherence. Retrospective data from Optum's de-identified Clinformatics The analysis included 142,853 infants in C1, 27,211 infants in C2, and 53,306 infants in C3. Among infants with at least 8 months of follow-up from birth, three-primary-dose completion (receipt of all three doses within 8 months after birth) and adherence (receipt of doses at recommended times) were significantly higher before (C1 and C2) versus during (C3) COVID-19 (odds ratio [OR] 1.12 [95% confidence interval [CI] 1.07, 1.16] and OR 1.10 [95% CI 1.05, 1.15], respectively). A significantly higher percentage of infants received a booster dose before versus during COVID-19 (83.2% vs. 80.2%; OR 1.23; 95% CI 1.17, 1.29); similarly, booster dose adherence was higher before than during COVID-19 (51.2% vs. 47.4%; OR 1.17; 95% CI 1.13, 1.21). The odds of booster dose completion were 8.26 (95% CI 7.92, 8.60) and 7.90 (95% CI 7.14, 8.74) times as likely in infants who completed all three primary doses than in infants who did not complete primary doses before COVID-19 and during COVID-19, respectively. PCV13 full completion was lower during the COVID-19 pandemic compared with pre-pandemic (79.0% vs. 77.1%).
Identifiants
pubmed: 36219342
doi: 10.1007/s40121-022-00699-5
pii: 10.1007/s40121-022-00699-5
pmc: PMC9552144
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2141-2158Informations de copyright
© 2022. The Author(s).
Références
Wahl B, O’Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type B disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Glob Health. 2018;6(7):e744–57. https://doi.org/10.1016/S2214-109X(18)30247-X .
doi: 10.1016/S2214-109X(18)30247-X
pubmed: 29903376
pmcid: 6005122
Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49(RR-9):1–35. https://www.ncbi.nlm.nih.gov/pubmed/11055835 .
Gierke R, Wodi AP, Kobayashi M. Pneumococcal disease. https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html . Accessed Sep 12, 2021.
Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease–United States, 1998–2003. MMWR Morb Mortal Wkly Rep. 2005;54(36):893–7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16163262 .
Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-11):1–18.
pubmed: 21150868
Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf . Accessed June 17, 2022.
Wiese AD, Griffin MR, Grijalva CG. Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States. Expert Rev Vaccines. 2019;18(4):327–41. https://doi.org/10.1080/14760584.2019.1582337 .
doi: 10.1080/14760584.2019.1582337
pubmed: 30759352
pmcid: 6443450
Centers for Disease Control and Prevention. Pneumococcal disease surveillance and reporting. https://www.cdc.gov/pneumococcal/surveillance.html . Accessed Feb 10, 2022.
Simonsen L, Taylor RJ, Schuck-Paim C, Lustig R, Haber M, Klugman KP. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med. 2014;2(5):387–94. https://doi.org/10.1016/S2213-2600(14)70032-3 .
doi: 10.1016/S2213-2600(14)70032-3
pubmed: 24815804
Suaya JA, Gessner BD, Fung S, et al. Acute otitis media, antimicrobial prescriptions, and medical expenses among children in the United States during 2011–2016. Vaccine. 2018;36(49):7479–86. https://doi.org/10.1016/j.vaccine.2018.10.060 .
doi: 10.1016/j.vaccine.2018.10.060
pubmed: 30385056
Centers for Disease Control and Prevention. Active bacterial core surveillance report. Emerging Infections Program Network, Streptococcus pneumoniae, 2018. https://www.cdc.gov/abcs/reports-findings/survreports/spneu18.html . Accessed May 3, 2021.
Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68(46):1069–75. https://doi.org/10.15585/mmwr.mm6846a5 .
doi: 10.15585/mmwr.mm6846a5
pubmed: 31751323
pmcid: 6871896
Centers for Disease Control and Prevention. Active bacterial core surveillance report. Emerging Infections Program Network, Streptococcus pneumoniae, 2019. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2019.pdf . Accessed Jul 18, 2022.
Deloria Knoll M, Park DE, Johnson TS, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity. Pediatr Infect Dis J. 2014;33 Suppl 2:S119–29. https://doi.org/10.1097/inf.0000000000000079 .
Jayasinghe S, Chiu C, Quinn H, Menzies R, Gilmour R, McIntyre P. Effectiveness of 7- and 13-valent pneumococcal conjugate vaccines in a schedule without a booster dose: a 10-year observational study. Clin Infect Dis. 2018;67(3):367–74. https://doi.org/10.1093/cid/ciy129 .
doi: 10.1093/cid/ciy129
pubmed: 29471432
Farrar JL, Nsofor C, Childs L, Koboyashi M, Pilishvili T. Systematic review of 13-valent penumococcal conjugate vaccine effectiveness against vaccine-type invasive pneumococcal disease among children. International Symposium on Pneumococci and Pneumococcal Diseases. Toronto, Canada; 2022.
Perdrizet J, Pustulka I, Forbes C, Horn E, Gessner BD, Hayford K. Systematic literature review of the 13-valent pneumococcal conjugate vaccine (PCV13) effectiveness against invasive pneumococcal disease in children globally. Infectious Disease Week. Washington, D.C.; 2022.
Hill HA, Yankey D, Elam-Evans LD, Singleton JA, Sterrett N. Vaccination coverage by age 24 months among children born in 2017 and 2018—National Immunization Survey-Child, United States, 2018–2020. MMWR Morb Mortal Wkly Rep. 2021;70(41):1435–40. https://doi.org/10.15585/mmwr.mm7041a1 .
doi: 10.15585/mmwr.mm7041a1
pubmed: 34648486
pmcid: 8631285
Office of Disease Prevention and Health Promotion. Healthy people 2020 immunization and infectious diseases: objectives. https://www.healthypeople.gov/2020/topics-objectives/topic/immunization-and-infectious-diseases/objectives . Accessed Dec 1, 2021.
Santoli JM, Lindley MC, DeSilva MB, et al. Effects of the COVID-19 pandemic on routine pediatric vaccine ordering and administration—United States, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(19):591–3. https://doi.org/10.15585/mmwr.mm6919e2 .
doi: 10.15585/mmwr.mm6919e2
pubmed: 32407298
Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25(1):2–10. https://doi.org/10.1002/pds.3891 .
Walton MK, Powers JH 3rd, Hobart J, et al. Clinical outcome assessments: conceptual foundation-report of the ISPOR clinical outcomes assessment—emerging good practices for outcomes research task force. Value Health. 2015;18(6):741–52. https://doi.org/10.1016/j.jval.2015.08.006 .
doi: 10.1016/j.jval.2015.08.006
pubmed: 26409600
pmcid: 4610138
Saxena S, Skirrow H, Bedford H. Routine vaccination during COVID-19 pandemic response. BMJ. 2020;369: m2392. https://doi.org/10.1136/bmj.m2392 .
doi: 10.1136/bmj.m2392
pubmed: 32546575
Dinleyici EC, Borrow R, Safadi MAP, van Damme P, Munoz FM. Vaccines and routine immunization strategies during the COVID-19 pandemic. Hum Vaccin Immunother. 2021;17(2):400–7. https://doi.org/10.1080/21645515.2020.1804776 .
doi: 10.1080/21645515.2020.1804776
pubmed: 32845739
McBride JA, Eickhoff J, Wald ER. Impact of COVID-19 quarantine and school cancelation on other common infectious diseases. Pediatr Infect Dis J. 2020;39(12):e449–52. https://doi.org/10.1097/INF.0000000000002883 .
doi: 10.1097/INF.0000000000002883
pubmed: 33031142
McNeil JC, Flores AR, Kaplan SL, Hulten KG. The indirect impact of the SARS-CoV-2 pandemic on invasive group a Streptococcus, Streptococcus pneumoniae and Staphylococcus aureus infections in Houston area children. Pediatr Infect Dis J. 2021;40(8):e313–6. https://doi.org/10.1097/INF.0000000000003195 .
doi: 10.1097/INF.0000000000003195
pubmed: 34250979
pmcid: 8279221
Van Groningen KM, Dao BL, Gounder P. Declines in invasive pneumococcal disease (IPD) during the COVID-19 pandemic in Los Angeles county. J Infect. 2022;85(2):174–211 https://doi.org/10.1016/j.jinf.2022.05.002 .
doi: 10.1016/j.jinf.2022.05.002
pubmed: 35550382
pmcid: 9081043
Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System, Weekly Tables of Infectious Disease Data. Division of Health Informatics and Surveillance. https://www.cdc.gov/nndss/data-statistics/index.html .
McLaughlin JM, Utt EA, Hill NM, Welch VL, Power E, Sylvester GC. A current and historical perspective on disparities in US childhood pneumococcal conjugate vaccine adherence and in rates of invasive pneumococcal disease: considerations for the routinely-recommended, pediatric PCV dosing schedule in the United States. Hum Vaccin Immunother. 2016;12(1):206–12. https://doi.org/10.1080/21645515.2015.1069452 .
doi: 10.1080/21645515.2015.1069452
pubmed: 26376039
Hill HA, Elam-Evans LD, Yankey D, Singleton JA, Kolasa M. National, state, and selected local area vaccination coverage among children aged 19–35 months—United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(33):889–96. https://doi.org/10.15585/mmwr.mm6433a1 .
doi: 10.15585/mmwr.mm6433a1
pubmed: 26313470
DeSilva MB, Haapala J, Vazquez-Benitez G, et al. Association of the COVID-19 pandemic with routine childhood vaccination rates and proportion up to date with vaccinations across 8 US health systems in the vaccine safety datalink. JAMA Pediatr. 2022;176(1):68–77. https://doi.org/10.1001/jamapediatrics.2021.4251 .
doi: 10.1001/jamapediatrics.2021.4251
pubmed: 34617975
Hill HA, Elam-Evans LD, Yankey D, Singleton JA, Kang Y. Vaccination coverage among children aged 19–35 months—United States, 2017. MMWR Morb Mortal Wkly Rep. 2018;67(40):1123–8. https://doi.org/10.15585/mmwr.mm6740a4 .
doi: 10.15585/mmwr.mm6740a4
pubmed: 30307907
pmcid: 6181261
Frew PM, Lutz CS. Interventions to increase pediatric vaccine uptake: an overview of recent findings. Hum Vaccin Immunother. 2017;13(11):2503–11. https://doi.org/10.1080/21645515.2017.1367069 .
doi: 10.1080/21645515.2017.1367069
pubmed: 28949819
pmcid: 5703404
The Commonwealth Fund. Beyond the case count: the wide-ranging disparities of COVID-19 in the United States. https://www.commonwealthfund.org/publications/2020/sep/beyond-case-count-disparities-covid-19-united-states . Accessed October 15, 2021.
Tai DBG, Sia IG, Doubeni CA, Wieland M. Disproportionate impact of COVID-19 on racial and ethnic minority groups in the United States: a 2021 update. J Racial Ethn Health Disparities. 2021. https://doi.org/10.1007/s40615-021-01170-w .
doi: 10.1007/s40615-021-01170-w
pubmed: 34647273
pmcid: 8513546